JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 1 OF 28 Virtual Diabetes Specialty Clinic: 
A Study Evaluating Remote Initiation of Continuous 
Glucose Monitoring  
 
Version Number: v. 4.1 
6 July 2021 
 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 2 OF 28 KEY ROLES  
 
Protocol Chair/Director  
Name, degree Grazia Aleppo, M.D. 
Title Protocol Chair 
Institution Name Northwestern University Feinberg School of Medicine  
 
JCHR Coordinating Center Director  
Name, degree Robin L. Gal, M.S.P.H. 
Title Project Director 
Institution Name Jaeb Center for Health Research 
 
Medical Monitor  
Name, degree Roy Beck, M.D., Ph.D. 
Title Executive Director 
Institution Name Jaeb Center for Health Research 
 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 3 OF 28 TABLE OF CONTENTS  
CHAPTER 1:  BACKGROUND INFORMATION  .................................................. ........................................... 10  
1.1 Introduction .................................. ................................................... .................................................. 10  
1.2 Rationale ..................................... ................................................... ................................................... . 11  
1.3 Potential Risks and Benefits .................. ................................................... ......................................... 12  
1.3.1 Known Potential Risks ....................... ................................................... ...................................... 12  
1.3.2 Known Potential Benefits .................... ................................................... ..................................... 12  
1.3.3 Risk Assessment ............................. ................................................... .......................................... 12  
1.4 General Considerations......................... ................................................... .......................................... 12  
 STUDY ENROLLMENT AND BASELINE DATA COLLECTION  ............................................... 13  
2.1 Participant Recruitment and Informed Consent .. ................................................... ........................... 13  
2.1.1 Informed Consent and Authorization Procedures  .................................................. ..................... 13  
2.2 Participant Inclusion Criteria ................ ................................................... .......................................... 13  
2.3 Participant Exclusion Criteria ................ ................................................... ......................................... 14  
2.4 Screening Procedures .......................... ................................................... ........................................... 14  
2.5 Collection of Baseline Data and Testing ....... ................................................... ................................. 14  
2.5.1 HbA1c ....................................... ................................................... ............................................... 15  
2.6 CGM System .................................... ................................................... .............................................. 15  
2.7 Blinded CGM ................................... ................................................... .............................................. 15  
2.8 Psychosocial Screening Questionnaires ......... ................................................... ................................ 16  
 STUDY PROCEDURES AND DATA COLLECTION  .................................................. ................ 17  
3.1 Overview ...................................... ................................................... .................................................. 17  
3.2 Virtual Clinic Team Interactions with Study Par ticipant .......................................... ........................ 17  
3.2.1 Virtual Clinic Team Interactions with Persona l Healthcare Provider ............................. ............ 17  
3.3 CGM Initiation (Unblinded Use) ................ ................................................... .................................... 17  
3.4 CGM Use and Data Interpretation ............... ................................................... ................................... 18  
3.5 Insulin Dose Changes .......................... ................................................... ........................................... 18  
3.5.1 Decision Support ............................ ................................................... .......................................... 18  
3.5.2 Personal Healthcare Provider Notification ... ................................................... ............................ 18  
3.6 Follow-up Data Collection ..................... ................................................... ........................................ 18  
3.6.1 HbA1c ....................................... ................................................... ............................................... 18  
3.7 Data Uploads .................................. ................................................... ................................................ 19  
3.8 Insulin Delivery and Collection of Insulin Data  .................................................. .............................. 19  
 QUESTIONNAIRES  .................................................. ................................................... ............ 20  
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 4 OF 28 
 MISCELLANEOUS CONSIDERATIONS  .................................................. ................................. 21  
5.1 Adverse Events ................................ ................................................... ............................................... 21  
5.2 Device Issues ................................. ................................................... ................................................. 2 1  
5.3 Study Costs ................................... ................................................... .................................................. 21  
5.4 Participant Compensation ...................... ................................................... ......................................... 21  
5.5 Participant Withdrawal ........................ ................................................... ........................................... 21  
5.5.1 Pregnancy ................................... ................................................... .............................................. 22  
5.6 Contact Information ........................... ................................................... ............................................. 22  
5.6.1 Personal Healthcare Provider Information .... ................................................... ........................... 22  
5.7 Confidentiality ............................... ................................................... ................................................. 2 2  
5.8 Quality Assurance and Monitoring .............. ................................................... ................................... 22  
 STATISTICAL CONSIDERATIONS  .................................................. ........................................ 24  
6.1 Statistical and Analysis Plan ................. ................................................... .......................................... 24  
6.2 Sample Size ................................... ................................................... ................................................. 2 4  
6.3 Outcome Measures .............................. ................................................... ........................................... 24  
6.4 Description of Statistical Methods............. ................................................... ..................................... 24  
6.4.1 Analysis Cohorts ............................ ................................................... .......................................... 24  
6.5 Analysis of Efficacy Outcomes ................. ................................................... ..................................... 24  
6.6 Subgroup Analyses ............................. ................................................... ............................................ 25  
6.7 Safety Analyses ............................... ................................................... ............................................... 25  
6.8 Baseline Descriptive Statistics ............... ................................................... ......................................... 25  
6.9 Multiple Comparisons/Multiplicity ............. ................................................... ................................... 25  
6.10 Additional Analyses .......................... ................................................... ........................................... 25  
 ETHICS /P ROTECTION OF HUMAN PARTICIPANTS  .................................................. ............ 26  
7.1 Ethical Standard .............................. ................................................... ................................................ 26  
7.2 Institutional Review Boards ................... ................................................... ........................................ 26  
7.3 Informed Consent Process ...................... ................................................... ........................................ 26  
7.3.1 Consent Procedures and Documentation ........ ................................................... .......................... 26  
 REFERENCES  .................................................. ................................................... .................... 27  
 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 5 OF 28 LIST OF ABBREVIATIONS  
ABBREVIATION DEFINITION 
BGM Blood Glucose Meter 
CDC  Centers for Disease Control and Prevention 
CDCES Certified Diabetes Care and Education Special ist 
CFR Code of Federal Regulations 
CGM Continuous Glucose Monitor 
DKA Diabetic Ketoacidosis  
FDA Food and Drug Administration 
GCP Good Clinical Practice  
HbA1c Hemoglobin A1c 
IRB Institutional Review Board 
MDI Multiple Daily Injections 
SH Severe Hypoglycemia 
T1D Type 1 Diabetes 
T2D Type 2 Diabetes 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 6 OF 28 PROTOCOL SUMMARY  
PARTICIPANT AREA DESCRIPTION 
Title Virtual Diabetes Specialty Clinic: A Study Evaluati ng Remote Initiation 
of Continuous Glucose Monitoring  
Précis This study will assess feasibility and efficacy of establishing a virtual 
diabetes clinic with a focus on introduction of CGM  technology and 
ongoing CGM use to minimize such rate-limiting fact ors as geography, 
cost and access to specialty care  
Objectives The objective of this study is to evaluate a virtua l diabetes clinic model, 
for adults with either T1D or T2D, that supports in tegration of CGM into 
diabetes self-management and evaluates use of decis ion support 
technology  within the virtual cli nic model . 
Study Design Single -arm prospective longitudinal study  
Eligibility Criteria Inclusion Criteria 
 Age >18 years old 
 Diagnosis of type 1 diabetes or type 2 diabetes and  using insulin 
therapy (at least 3 injections of insulin per day o r insulin pump that 
is compatible with Tidepool software) Multiple daily injection (MDI) 
users must be willing to use a device provided by t he study that 
records the injection dosages and/or enter insulin dosing 
information through an app  
 See a healthcare provider at least once a year 
 Resident of United States and plan to reside in the  U.S. for the 
duration of the study * This requirement is due to virtual clinic 
license requirements and U.S. use restrictions for some study 
software and devices. Not all U.S. states may be el igible for 
inclusion due to virtual clinic license status.  
 Use either an Android or iOS smartphone that is com patible with app 
requirements that are needed for the study 
 Access to a compatible computer with internet 
 Understand written and spoken English 
 Willing and able to follow the study procedures as instructed 
Exclusion Criteria 
 Current use of a closed loop system where an insuli n pump and 
CGM share information and insulin dose is automatic ally adjusted 
based on glucose reading 
 Current CGM use where Time in Range is ≥60% or Time  <54%  
≤1.0%). 
 Current use of any off-label glucose-lowering medic ations for 
diabetes type (Example: T1D use of non-insulin, ant i-diabetic 
medications including SGLT2 inhibitors) * Use of such medications 
during the study will also be prohibited.  
 Females who are pregnant, intending to become pregn ant, or 
breastfeeding during the study 
 Current renal dialysis or plan to begin renal dialy sis during the study 
 Active cancer treatment 
 Extreme visual or hearing impairment that would imp air ability to 
use real-time CGM 
 Known adhesive allergy/prior skin reaction or skin reaction 
identified during the blinded CGM use phase that wo uld preclude 
continued CGM use 
 Participation in a different diabetes management st udy during the 
study 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 7 OF 28 PARTICIPANT AREA DESCRIPTION 
 Planned relocation to a state other than current st ate of residence 
during the study if virtual clinic is not licensed in the new state. 
Individuals working routinely in a state other than  current state of 
residence in the next six months are also ineligibl e if the virtual 
clinic is not licensed in that state.  
Sample Size The recruitment target is 300  initiating CGM .  
Outcomes Efficacy Outcomes: CGM use; CGM metrics for hypoglycemia (<54 and 
<70 mg/dL), hyperglycemia (>180 and >250 mg/dL), ti me in range (70-
180 mg/dL), mean glucose, and glycemic variability (coefficient of 
variation); HbA1c; participant- reported outcomes i ncluding psychosocial 
and diabetes treatment satisfaction questionnaires 
Safety Outcomes: Severe hypoglycemia, diabetic ketoacidosis, 
hospitalizations , and emergency room visits  
Participant Duration Study participation will be up to 12 months.  
Protocol Overview/Synopsis 
 Patient Population 
Adults ≥ 18 years with type 1 diabetes or type 2 di abetes using insulin 
therapy will be enrolled. Although the primary focu s of the study is to 
enroll non-CGM users, CGM users whose glycemic cont rol is suboptimal 
can be enrolled. Potential participants may be recr uited through insurance 
providers, primary care networks, or health care pr oviders. 
 
Baseline Data Collection 
Baseline data collected will include demographics, height and weight, 
socioeconomic status, diabetes history, knowledge o f and experience with 
diabetes devices, medical history and medications, and health-related 
physical activity. Questionnaires will collect info rmation related to 
hypoglycemia awareness, treatment satisfaction, and  psychosocial issues. 
Participant contact information will be collected. Contact information for 
the participant’s diabetes healthcare provider will  also be collected. 
 
HbA1c 
Participant will receive fingerstick HbA1c kits tha t will be sent to a 
central lab for measurement after enrollment and at  13 weeks, 26 weeks, 
39 weeks, and 52 weeks. 
 
Contact between Study Team and Participant 
Each participant will be assigned to work with virt ual clinic team 
members. Mental health service support options for diabetes-related 
mental health issues will be discussed as needed. 
 
Virtual clinic team members will check in with part icipants during the 
initial six months of study follow up to review CGM  data and 
recommendations related to diabetes management. Par ticipants who 
continue in the optional extended follow-up phase a fter the first six 
months can contact the virtual clinic as needed.  
 
CGM Use 
Participants who do not currently use a CGM will us e a blinded CGM 
device for a single sensor wear period prior to CGM  initiation. 
Participants may be asked to use a blinded CGM for an additional sensor 
wear period(s) if enough CGM data are not available  to establish a 
baseline that can be used as baseline comparator da ta. Current CGM users 
will be asked to share their CGM data to confirm th at they meet study 
eligibility criteria and to establish a baseline th at can be used as baseline 
comparator data. Virtual training will include CGM set up, sensor 
insertion, alerts and alarms, uploading data, and v isualizing data. 
 
Changes in Insulin Dosing  
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 8 OF 28 PARTICIPANT AREA DESCRIPTION 
If the virtual clinic team believes that changes in  insulin type or dosing 
should be considered, they will work with the parti cipant to implement 
any such changes. Decision support tools, which inc lude use of a mobile 
application, may be used if available to provide th e virtual clinic team 
with potential recommendations regarding i nsulin use.  
 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79  P AGE 9 OF 28 SCHEDULE OF STUDY VISITS AND PROCEDURES  1 
This is a remote study design with virtual visits; eligibility and other study questionnaires are by p articipant self-report.  2 3 
 
   Virtual Clinic Training Phase 
(0-13 Weeks) Virtual Clinic 
Follow Up 
Phase Optional 
Extended 
Participant 
Follow Up 
 
Enrollment Initial Virtual 
Clinic Contact Baseline CGM 
Data Collection Training 1 
(Week 0) Training 2 
(Week 1)  Training 3 
(Week 3)  CGM Follow 
Up 
(Weeks 4, 8) CGM Follow Up 
(Week 13)  Follow up 
(>13-26 
Weeks) Follow Up 
(>26-52 Weeks) 
TARGET WINDOW  Within 7 Days 
from 
Completion of 
Enrollment 
Questionnaires  Day 0 Day 7-14 Day 21-28  Weeks 12-14   
ICF  Eligibility Confirmation X        X * X * 
Baseline Data Collection  Contact Information 
 Demographics 
 Medical History 
 Questionnaires X  X        
Follow-Up Data Collection**     X X X X X X 
HbA1c***   X     X X X 
Video Tutorials / Access to Resource Materials  Examples: CGM Overview Parts of CGM Examples: HbA1c Sample Collection CGM Setup Examples: Understanding Your Real-Time Data How to Change Sensor Examples: How to Upload CGM Data How to View Reports Understanding Your Ambulatory Glucose Profile / Data Patterns X X X X X 
Contact with Study Team †  X X CGM Initiation CGM Data 
Interpretation CGM Data 
Review 
Goal Setting X X X X 
CGM Use ††   ~2 Week Blinded 
CGM Use †††  Start of 26-Week 
Unblinded CGM 
Use X X X X X X 
*. Participants will be asked to extend follow up fo r an additional 26 weeks and sign an addendum ICF i f they plan to continue to use CGM after the first 26 weeks. Virtual Clinic follow up will be availabl e to participants on an as-needed 
basis after the first 26 weeks. **Participants will be asked to complete questionna ires monthly after CGM Initiation. A final question naire will be elicited at the earlier of CGM discon tinuation or completion of study follow up (~52 wee ks). 
***HbA1c checks prior to unblinded CGM initiation, and at 3-month intervals following CGM initiation ( ~13 weeks, 26 weeks, 39 weeks, and 52 weeks)  
†Follow up may be via phone, text, virtual (i.e. Sky pe), or app. outside of scheduled training. Additio nal follow up may be conducted as needed. Participa nts may follow up with study team as needed. 
††CGM supplied for blinded data collection will be pr ovided. CGM supplies for six months of unblinded us e will be provided for those who successfully compl ete blinded data collection. 
††† Current CGM users are not required to wear blinded CGM unless current CGM data cannot be shared to est ablish baseline. 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 10  OF 28 Chapter 1: Background Information 4 
1.1  Introduction 5 
The advent of home blood glucose meter (BGM) testin g from a fingerstick in the 1980s had a 6 
major impact on the management of diabetes, particu larly in individuals using insulin. While 7 
BGMs remain the method of glucose monitoring for mo st people with diabetes, continuous 8 
glucose monitoring (CGM) systems are now available and have replaced BGM testing for 9 
primary glucose monitoring in an increasing number of adults and children with type 1 diabetes 10 
(T1D) and some with type 2 diabetes (T2D). 11 
The CGM device has a sensor that is inserted in the  subcutaneous space and measures the 12 
interstitial fluid glucose concentration. Some CGMs , such as the Dexcom G6, provide real-time 13 
glucose measurements every five minutes with alerts  for rising or dropping glucose levels and 14 
threshold alarms when a preset hyperglycemia or hyp oglycemia level is reached. Other CGMs 15 
such as the Abbott FreeStyle Libre, which also has been referred to as flash glucose monitoring, 16 
show glucose levels only when the user passes the r eceiver over the sensor to transmit the 17 
glucose data to the receiver; glucose recordings ar e every 15 minutes. 18 
The accuracy of current generation CGMs approaches that of blood glucose meters. For the 19 
current generation of the Dexcom and Abbott sensor,  the mean absolute relative difference, a 20 
common metric for assessing accuracy when sensor gl ucose values are compared with reference 21 
glucose values, is about 10% or lower, which is in about the middle of the range of accuracy of 22 
current blood glucose meters 1,2 . This accuracy is what led the FDA to approve the device for 23 
non-adjunctive use in dosing insulin. 24 
The efficacy of CGM has been demonstrated in random ized trials of adults and youth with type 1 25 
diabetes (T1D) 3-10 , adults with type 2 diabetes (T2D) using insulin 11-13 , and in a registry of adults 26 
and youth with T1D 14 ; including reductions in HbA1c levels, duration of  hyperglycemia and 27 
hypoglycemia, and increased time spent with glucose  levels between 70 and 180 mg/dL, which is 28 
the target range. Studies not only demonstrated imp rovement in HbA1c and reduction in 29 
hypoglycemia but also showed that after six months,  approximately 90% of individuals were 30 
using CGM on a daily or near-daily basis. CGM users  have reported substantial satisfaction with 31 
use of the device and improved quality of life.3,9,15-18  32 
Studies have demonstrated the benefits of CGM in in dividuals with T1D or T2D treated with 33 
multiple daily injections of insulin 3,5,6,9,15,16 . In the T1D Exchange registry, CGM use 34 
(predominately Dexcom) was associated with lower Hb A1c levels irrespective of whether a 35 
pump or injections are used for insulin delivery. M ean HbA1c was 9.1% in individuals not using 36 
a pump or CGM, 8.6% in those using a pump but not a  CGM, 7.9% in those using both a pump 37 
and CGM, and 8.0% in those using injections and CGM . 38 
Current generation CGMs have been shown to have a g ood safety profile. The ease of insertion, 39 
lack of need for calibration or routine blood gluco se meter testing, and extension of sensor life 40 
have all made the initiation of CGM easier. Thus, t he time has come to consider initiation of 41 
CGM use as similar to BGM use. 42 
CGM use has been endorsed for individuals with T1D by the American Diabetes Association, 43 
the American Association of Clinical Endocrinologis ts, the Endocrine Society, and the 44 
International Society for Pediatric and Adolescent Diabetes. Despite these recommendations and 45 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 11  OF 28 the compelling evidence of the benefits of CGM, man y individuals with T1D or insulin-using 46 
T2D have not incorporated CGM into their diabetes m anagement. Although there are not specific 47 
data to cite, it is likely that the low rate of CGM  adoption partially reflects a lack of awareness 48 
about CGM among primary care providers, who are res ponsible for the care of not only most 49 
adults with type 2 diabetes but also those with typ e 1 diabetes 19-21 . Lack of provider resources to 50 
introduce and incorporate CGM into patient diabetes  self-management may also be a limiting 51 
factor to technology adoption, as usage is low even  among some leading diabetes centers 14,22 . 52 
Although demand for endocrinology care continues to  grow, access to specialized care may be 53 
impacted by geographic isolation and a shortage in the number of endocrinologists in the United 54 
States. 55 
A recently completed feasibility study assessed whe ther adults with T1D or T2D using insulin 56 
could be trained virtually, outside of the clinic, to initiate and use CGM as part of their diabetes 57 
self-management. This study demonstrated that a vir tual approach outside of the clinic can be 58 
used for successful CGM initiation and incorporatio n into diabetes self-management for adults 59 
with T1D or T2D using insulin. There was a substant ial reduction in HbA1c in most participants, 60 
as well as a reduction in estimated mean glucose, w ith an increase in the amount of time in range 61 
spent with glucose levels between 70 and 180 mg/dL,  which is the generally accepted target 62 
range for most adults with T1D or T2D (excluding pr egnancy) 23 . Further, participant-reported 63 
outcomes evaluated before and after exposure to the  virtual clinic revealed improvements in 64 
glucose monitoring satisfaction, confidence in trea ting hypoglycemia, and reductions in diabetes 65 
distress. 66 
It is important for those using CGM to understand h ow to use the data from the CGM. This 67 
includes looking at patterns and trends to understa nd what their glucose is doing and how it 68 
changes while sleeping, in between meals, and durin g periods of exercise and stress. 69 
Understanding CGM data extends beyond responding to  alerts and warnings when levels are too 70 
high and too low. Current CGM users may benefit fro m virtual clinic support to better 71 
understand their CGM data, as not all CGM users mee t goals for time in range or HbA1c target. 72 
We plan to assess feasibility and efficacy of estab lishing a virtual diabetes clinic with a focus on 73 
introduction and training related to use of CGM tec hnology and ongoing CGM use to minimize 74 
such rate-limiting factors as geography, cost and a ccess to specialty care. The virtual diabetes 75 
clinic model will include a comprehensive care team  with support for diabetes technology such 76 
as CGM and decision support to align with current r ecommendations in diabetes care. Screening 77 
for and access to diabetes-related mental health su pport will also be included. 78 
1.2  Rationale 79 
The objective of this study is to evaluate a virtua l diabetes clinic model, for adults with either 80 
T1D or T2D, that supports integration of CGM into d iabetes self-management and evaluates use 81 
of decision support technology within the virtual c linic model. The virtual diabetes clinic model 82 
will also include mental health screening and suppo rt services, particularly for diabetes-related 83 
issues. 84 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 12  OF 28 1.3  Potential Risks and Benefits 85 
1.3.1  Known Potential Risks 86 
The fingerstick to collect the HbA1c sample could c ause bruising and/or pain at the collection 87 
site. 88 
The CGM sensor may produce pain when it is inserted  into the skin. There is a low risk for 89 
developing a local skin infection at the site of th e sensor needle placement. Itchiness, redness, 90 
bleeding, and bruising at the insertion site may oc cur as well as local tape allergies. On rare 91 
occasions, the sensor may break and leave a small p ortion of the sensor under the skin that may 92 
cause redness, swelling, or pain at the insertion s ite. 93 
There is a small risk of hypoglycemia when using CG M for insulin dosing if the CGM glucose 94 
value is substantially higher than the true glucose  level. There also is a small risk of 95 
hyperglycemia if the CGM glucose is substantially l ower than the true glucose. 96 
There is a risk of breach of confidentiality. All d ata will be maintained in a secure database with 97 
restricted access to help assure confidentiality. D ata downloaded from diabetes devices will be 98 
collected for the study. Some people may be uncomfo rtable with the researchers having such 99 
detailed information about their daily diabetes hab its. 100 
There is the possibility that completion of questio nnaires could make the participant feel 101 
uncomfortable. 102 
The study may include other risks that are unknown at this time. 103 
1.3.2  Known Potential Benefits 104 
It is likely that the participants will benefit fro m access to a virtual diabetes specialty clinic and  105 
using CGM in the study. However, it is possible tha t participants will not directly benefit from 106 
being a part of this study. 107 
1.3.3  Risk Assessment 108 
The protocol risk assessment for this study has bee n categorized as not greater than minimal risk. 109 
1.4  General Considerations 110 
The study is being conducted in compliance with the  policies described in the study policies 111 
document, with the ethical principles that have the ir origin in the Declaration of Helsinki, with 112 
the protocol described herein, and with the standar ds of Good Clinical Practice (GCP). 113 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 13  OF 28 
 Study Enrollment and Baseline Data Collection 114 
2.1  Participant Recruitment and Informed Consent 115 
Adults (age >18 years) with type 1 diabetes or type  2 diabetes using insulin therapy (Tidepool- 116 
compatible pump or injections) will be enrolled. Al though the primary focus of the study is to 117 
enroll non-CGM users, CGM users whose glycemic cont rol is suboptimal can be enrolled. 118 
Participation will be limited to U.S. residents in states where the virtual clinic is licensed; state 119 
eligibility will be verified as part of screening. Potential participants may be recruited through 120 
insurance providers, primary care networks, or heal th care providers. Potential participants also 121 
may become aware of the study by other means, such as another study participant. 122 
Up to 800 individuals may sign the informed consent  form to initiate screening. Enrollment will 123 
proceed with the goal of at least 300 participants initiating training for CGM use with the Virtual 124 
Clinic. The goal will be to limit T2D enrollment to  no more than 100. Recruitment efforts will be 125 
focused on participants who receive diabetes care i n a primary care setting rather than through an 126 
endocrinologist, with a goal of having at least 225  who have not seen an endocrinologist in the 127 
past six months. Eligible participants will be incl uded without regard to gender, race, or 128 
ethnicity. 129 
The goal will be to include at least 50 participant s <25 years of age and at least 50 participants 130 
>65 years of age. 131 
2.1.1  Informed Consent and Authorization Procedures 132 
Individuals who indicate that they are interested w ill be directed to a website with information 133 
about the study. Interested individuals will be abl e to communicate with study staff who can 134 
answer questions about the study as part of the inf ormed consent process. Individuals who want 135 
to participate in the study will sign the Instituti onal Review Board (IRB) approved electronic 136 
consent form. As part of the informed consent proce ss, each participant will be asked to sign an 137 
authorization for release of personal information. Participants will be asked to sign an addendum 138 
consent for follow up after the first 6 months if t hey plan to continue use of CGM. 139 
2.2  Participant Inclusion Criteria 140 
Individuals must meet all the following inclusion c riteria in order to be eligible to participate in 141 
the study: 142 
1.  Age >18 years old 143 
2.  Diagnosis of type 1 diabetes or type 2 diabetes and  using insulin therapy (at least 3 injections 144 
of insulin per day or insulin pump that is compatib le with Tidepool software) 145 
Multiple daily injection (MDI) users must be willin g to enter insulin dosing information 146 
through an app 147 
3.  See a healthcare provider at least once a year 148 
4.  Resident of United States and plan to reside in the  U.S. for the duration of the study 149 
This requirement is due to virtual clinic license r equirements and U.S. use restrictions for 150 
some study software and devices. Not all U.S. state s may be eligible for inclusion due to 151 
virtual clinic license status. 152 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 14  OF 28 5.  Use either an Android or iOS smartphone that is com patible with app requirements that are 153 
needed for the study 154 
6.  Access to a compatible computer with internet 155 
7.  Understand written and spoken English 156 
8.  Willing and able to follow the study procedures as instructed 157 
2.3  Participant Exclusion Criteria 158 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from 159 
study participation: 160 
1.  Current use of a closed loop system where an insuli n pump and CGM share information and 161 
insulin dose is automatically adjusted based on glu cose reading 162 
2.  Current CGM use where Time in Range is ≥60.0% or Ti me <54% is ≤1.0%. 163 
3.  Current use of any off-label glucose-lowering medic ations for diabetes type (Example: T1D 164 
use of non-insulin, anti-diabetic medications inclu ding SGLT2 inhibitors) 165 
Use of such medications during the study will also be prohibited. 166 
4.  Females who are pregnant, intending to become pregn ant, or breastfeeding during the study 167 
5.  Current renal dialysis or plan to begin renal dialy sis during the study 168 
6.  Active cancer treatment 169 
7.  Extreme visual or hearing impairment that would imp air ability to use real-time CGM 170 
8.  Known adhesive allergy/prior skin reaction or skin reaction identified during the blinded 171 
CGM use phase that would preclude continued CGM use  172 
9.  Participation in a different diabetes management st udy during the study 173 
10.  Planned relocation to a state other than current st ate of residence during the study if virtual 174 
clinic is not licensed in the new state. 175 
Individuals working routinely in a state other than  current state of residence in the next six 176 
months are also ineligible if the virtual clinic is  not licensed in that state. 177 
2.4  Screening Procedures 178 
Participants will be asked to confirm eligibility b y completing a screening questionnaire. 179 
Participants who pass screening will be asked to pr ovide baseline data. Current CGM users will 180 
also be asked to share their CGM data to confirm el igibility. If current data cannot be shared, 181 
current CGM users will be asked to complete blinded  CGM data collection.  Non-CGM users 182 
will also be asked to complete blinded CGM data col lection. Participants will be asked to submit 183 
a baseline HbA1c sample 184 
2.5  Collection of Baseline Data and Testing 185 
After informed consent is signed, baseline data wil l be collected, including the following: 186 
 Contact information 187 
 Date of birth 188 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 15  OF 28  Demographics 189 
 Height and weight 190 
 Socio-economic information such as education, incom e, and insurance 191 
 Name and contact information of healthcare provider  for diabetes management 192 
 Diabetes history, including diabetes duration, prio r management, insulin delivery method, 193 
meal bolus determination method, prior severe hypog lycemia (SH), prior diabetic 194 
ketoacidosis (DKA) 195 
 Medical history 196 
 Medications, including but not limited to medicatio ns other than insulin being used for 197 
glycemic control  198 
 Prior CGM experience and knowledge, including why C GM is not used 199 
 General health 200 
 Questionnaires (see Chapter 4) 201 
 Finger stick to measure HbA1c 202 
 Blinded CGM Data Collection 203 
2.5.1  HbA1c 204 
HbA1c will be measured at a central laboratory. The  participant will be sent a kit, which will 205 
include a blood collection tube and shipping materi als, to obtain a finger stick blood sample. The 206 
sample will be returned to the lab in a prepaid mai ler. Participants will be able to view their 207 
HbA1c results through the study website. 208 
2.6  CGM System 209 
Participants will use the Dexcom G6, which is a com mercially available CGM system. CGM 210 
data will be shared with CDCES and study team membe rs. 211 
Other sensors that become FDA approved during the c ourse of the study may be included as an 212 
option for participants. If additional sensors are included, the participants will be given 213 
information about CGM system options and will revie w the CGM systems with a study team 214 
member. A recommendation may be provided for one of  the systems based on discussion with 215 
the participant, or there may be an indication that  there is no specific recommendation. 216 
Participants will be able to select the CGM system that they prefer, regardless of 217 
recommendation. After a CGM system is selected, the  participant may be asked why that system 218 
was selected. 219 
2.7  Blinded CGM 220 
Non-CGM users will use a blinded CGM device for a s ingle sensor wear period (usually at least 221 
10 days) prior to CGM initiation. Current CGM users  will be asked to use a blinded CGM device 222 
for a single sensor wear period if their current CG M data cannot be successfully shared to 223 
confirm eligibility. Study supplies required for bl inded CGM data collection will be sent to the 224 
participant by mail. An Android phone may be provid ed which is used as a receiver to collect 225 
data from the blinded Dexcom G6 Pro. Current non-De xcom CGM users, including pump users 226 
with integrated CGM should continue to use their pe rsonal CGM for glucose management. 227 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 16  OF 28 A virtual clinic team member will be available to a nswer questions about blinded CGM use. The 228 
participants will not be able to see the glucose va lues and will be expected to follow their normal 229 
diabetes management practice during this blinded CG M use period. The goal will be to obtain 230 
ten days of blinded data. Participants may be asked  to use a blinded CGM for an additional 231 
sensor wear period if enough CGM data are not avail able to establish baseline comparator data. 232 
Participants will be dropped from the study if blin ded data cannot be obtained. Participants who 233 
have a serious skin reaction to the sensor during b linded CGM wear that precludes continued use 234 
of a sensor will be dropped. If additional FDA-appr oved CGM options are available for use in 235 
this study, the participant may be offered the oppo rtunity to try the other CGM system; in this 236 
case blinded data collection would be repeated with  another system. 237 
2.8  Psychosocial Screening Questionnaires  238 
Separate from the patient-reported outcome question naires, psychosocial screening 239 
questionnaires are administered to study participan ts 4 times during the study: as part of baseline 240 
data collection and 1, 2, and 3 months after unblin ded CGM initiation. These screening 241 
questionnaires are validated tools to evaluate depr ession, diabetes distress, and hypoglycemia 242 
fears. Questionnaire administration is repeated to ensure that the virtual clinic team delivering 243 
diabetes care is aware of any mental health issues that may make diabetes management harder 244 
for the study participant. An elevated score on any  of these questionnaires prompts an automated 245 
alert to the virtual clinic team (See section 3.2). 246 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 17  OF 28 
 Study Procedures and Data Collection 247 
3.1  Overview 248 
Training and data collection for the study will be completed remotely. Study supplies will be sent 249 
to the participant by mail. Participants will be fo llowed for up to 12 months or until they 250 
discontinue CGM use. After initial CGM training has  been completed, participants will continue 251 
to be followed by the virtual clinic team for six m onths. After the initial six months of follow up, 252 
participants who decide to continue to use CGM will  be asked to extend follow up for an 253 
additional 6 months and complete questionnaires, su bmit HbA1c samples, and share CGM data. 254 
During the extended follow up phase, participants w ill be able to contact the virtual clinic with 255 
questions or to request assistance as needed. 256 
3.2  Virtual Clinic Team Interactions with Study Partici pant 257 
Each participant will be assigned to work with virt ual clinic team members who are able to 258 
provide clinical care for diabetes management in th e state where the participant resides. The 259 
virtual clinic team members will teach participants  to use and incorporate CGM into self- 260 
management practices. Mental health service support  options for diabetes-related mental health 261 
issues will be discussed as needed. 262 
The virtual clinic team will assist with initiation  of CGM, as needed, after CGM supplies are 263 
received and will provide additional training after  approximately one week of CGM use, and 264 
after approximately three weeks of CGM use. Virtual  clinic team members will check in with 265 
participants during study follow up to review CGM d ata and recommendations related to 266 
diabetes management, and additional virtual visits may be scheduled. Contact with a virtual 267 
clinic team member may be requested by the particip ant at any time. 268 
In addition, the virtual clinical team member will follow up with the study participant if there is 269 
an elevated score on the psychosocial screening que stionnaires (section 2.8). The virtual clinic 270 
team will follow their internal processes for diabe tes related mental health services support. 271 
Participants may be offered the opportunity to work  with a behavioral health coach from the 272 
virtual clinic team at no cost. Follow up communica tion with a personal healthcare provider is at 273 
the discretion of the virtual clinic for any issues  which may require additional support. 274 
The virtual clinic team member(s) may interact with  the participant through texts, emails, phone 275 
calls and/or virtual training sessions. Phone calls  may be recorded. Additional mobile 276 
applications may be required to facilitate communic ations between participant and virtual clinic 277 
team member(s) depending on program enrollment. 278 
3.2.1  Virtual Clinic Team Interactions with Personal Heal thcare Provider 279 
Communications will be provided to the health care provider whom the participant designates for 280 
diabetes management, so that the provider is aware of the participant’s study participation and of 281 
information related to care or treatment (See secti on 3.5.2). 282 
3.3  CGM Initiation (Unblinded Use) 283 
CGM supplies will be sent to the participant by mai l. Device user manuals will be provided 284 
along with study instructions. The study website wi ll include a resources page which may 285 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 18  OF 28 include device user manuals, study instructions and  tutorials, and links to standard of care 286 
diabetes-related educational information recommende d by the study team. Live webinars may be 287 
available for those who want to receive additional education about diabetes management and use 288 
of CGM technology. 289 
A virtual training session will be arranged with th e participant’s virtual clinic team member to 290 
answer questions regarding CGM set up, sensor inser tion, alerts and alarms, uploading data, and 291 
visualizing data. 292 
3.4  CGM Use and Data Interpretation 293 
After the initial training to initiate CGM use, par ticipants will receive additional training on how 294 
to use data visualization tools and how to use the CGM data to make self-management changes 295 
in insulin dosing, meals, exercise, etc. The traini ng approach may vary by participants’ age 296 
and/or comfort with technology. 297 
3.5  Insulin Dose Changes 298 
If the virtual clinic team believes that changes in  insulin type or dosing should be considered, 299 
they will work with the participant to implement an y such changes. 300 
3.5.1  Decision Support 301 
Decision support tools, which include use of a mobi le application, may be used, if available, to 302 
provide the virtual clinic team with potential reco mmendations regarding insulin use. The virtual 303 
clinic team will review all data, including any ava ilable decision support recommendations, 304 
before making recommendations. Use of decision supp ort for T1D is approved for 305 
recommendations to providers. Use for T2D is invest igational. For both T1D and T2D, use of 306 
decision support would be classified as a Non-Signi ficant Risk as the decision support 307 
recommendation is made to the provider and does not  replace virtual clinic team review of all 308 
available CGM and insulin data when considering man agement decisions. 309 
3.5.2  Personal Healthcare Provider Notification 310 
The health care provider whom the participant desig nates for diabetes management will be 311 
informed of insulin dose and other medication chang es. 312 
3.6  Follow-up Data Collection 313 
Data will be collected throughout study follow up a nd will include information related to 314 
diabetes management, psychosocial outcomes, adverse  event and device issues, patient-related 315 
outcomes and questionnaires, HbA1c measurement, and  upload of device data. 316 
3.6.1  HbA1c 317 
HbA1c will be collected at approximately 13, 26, 39 , and 52 weeks and measured at a central 318 
laboratory. A kit, which will include a blood colle ction tube and shipping materials, will be sent 319 
to the participant to obtain a fingerstick blood sa mple and return the sample to the lab. 320 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 19  OF 28 3.7  Data Uploads 321 
Instructions for downloads and data sharing from di abetes-related care devices and applications 322 
used for the study will be reviewed with each parti cipant as part of their training. 323 
3.8  Insulin Delivery and Collection of Insulin Data 324 
Participants will use their own insulin during the study. If the participant uses an insulin pump, 325 
training will include uploading (or linking) of the se devices.  326 
MDI users with a compatible insulin pen may be give n a Biocorp Mallya (Mallya) device to use 327 
during the study that automatically logs insulin do se. Mallya is a data collection device that 328 
automatically captures data such as date of injecti on, time of injection, insulin type, and dose. 329 
Mallya attaches directly to the insulin pen and doe s not alter how the pen is used. Mallya is 330 
intended for data collection purposes only, with mi nimal information communicated to the 331 
participant via the app or device. Mallya is an inv estigational device, and it is classified as a 332 
Non-Significant Risk device by the Sponsor. 333 
An app that is needed to transfer data from the dev ice used to log insulin dose will be installed 334 
on the participant’s personal smartphone. Participa nts will be trained on use of the device and 335 
app as needed. If a device that automatically logs insulin dose is not available, the participant 336 
may be asked to enter insulin doses directly throug h an app.  337 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 20  OF 28 
 Questionnaires 338 
Questionnaires are completed by all participants on  the study website. The responses to the 339 
outcome surveys are not monitored in real-time. The  procedures for administration are described 340 
in the study procedures manual. 341 
Measure DESCRIPTION 
Patient Health 
Questionnaire- 8 8-item survey to evaluate depression-related sympto ms; 3 minutes to 
complete 
Diabetes Distress 
Scale (Management 
Distress Items) 17-item management burden scale to measure the degr ee of distress 
related to diabetes; 4 minutes to complete. 
Fear of 
Hypoglycemia 
(Worry) 6- item survey to measure concerns about low blood sugar; 2 minutes 
to complete 
CDC Healthy Days 4 questions developed by the CDC to obtain a genera l assessment of 
physical and mental health; 2 minutes to complete 
Hypoglycemia 
Confidence Presents 8 common situations where hypoglycemia occ urs and 
evaluates level of confidence of how it can be mana ged in those 
situations; 4 minutes to complete. 
Diabetes Technology 
Attitudes 5-item survey to measure perceptions about the bene fits of diabetes 
technology and devices; 2 minutes to complete. 
Glucose Monitoring 
Satisfaction 15-item survey to evaluate treatment satisfaction/b urden; 4 minutes to 
complete. 
Sleep 1-item sleep survey that measures quality of sleep;  1 minute to 
complete 
Benefits and Burdens 
of CGM 16 items per section with 2 sections that list situ ations (e.g. ability to 
share data, glycemic events, physical activity) and  designation of 
whether they are barriers or benefits; 4 minutes to  complete. 
CGM 
Discontinuation 3-item survey; participants who discontinue CGM wil l be asked to 
complete this. 
Participants may also be asked to answer questions,  which have been approved by the IRB, 342 
regarding their participation experience. 343 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 21  OF 28 
 Miscellaneous Considerations 344 
5.1  Adverse Events 345 
Participants will be asked to complete questionnair es to report events that have occurred. For 346 
each event reported, the participant will be asked if the event could have been related to the use 347 
of CGM. 348 
If there is no response, the participant may be con tacted again to encourage questionnaire 349 
completion. 350 
Participants will be asked to report the following events: 351 
● Severe hypoglycemia 352 
o Reportable events will be defined as hypoglycemia d uring which the participant was 353 
impaired cognitively to the point that he/she was u nable to treat himself/herself, was 354 
unable to verbalize his/her needs, was incoherent, disoriented, and/or combative, or 355 
experienced seizure or loss of consciousness. 356 
● DKA 357 
o The participant will be asked if he/she was seen at  a health care facility and/or 358 
hospitalized and what the ketone level was if known . 359 
● Hospitalizations 360 
Adverse event data reported to virtual clinic team members and study staff will be collected.  361 
5.2  Device Issues 362 
Participants will also be asked to report the follo wing device issues: 363 
● Device-related events with potential impact on pa rticipant safety 364 
o Skin reactions at the sensor site will be reported as adverse events if they are 365 
classified as severe and/or required treatment. 366 
5.3  Study Costs 367 
CGM supplies will be provided for the first six mon ths of the study. Participants will be able to 368 
keep the provided CGM supplies after follow up has ended. Participants who plan to continue 369 
use of CGM after 6 months will need to work with th eir insurance provider to obtain approval 370 
for CGM. 371 
Costs of standard medical care for diabetes that wo uld occur even if the participant were not in 372 
this study, including insulin, will be the particip ant’s responsibility. 373 
5.4  Participant Compensation 374 
Participant compensation will be specified in the i nformed consent form. 375 
5.5  Participant Withdrawal 376 
Participation in the study is voluntary, and a part icipant may withdraw at any time. The reason 377 
for withdrawal will be collected. Additionally, at the time of withdrawal, the participant will be 378 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 22  OF 28 asked to complete device downloads and questionnair es. For participants who withdraw, their 379 
data will be used up until the time of withdrawal. 380 
Participants who do not complete baseline procedure s in a timely fashion or are noncompliant 381 
with respect to the protocol may be withdrawn. 382 
5.5.1  Pregnancy 383 
If pregnancy occurs, the participant will be withdr awn from the study. 384 
5.6  Contact Information 385 
Contact information for each participant, including  name, email address, mobile number, and 386 
mailing address will be provided to the coordinatin g center, the Jaeb Center for Health Research 387 
in Tampa, FL. Permission to obtain such information  will be included in the Informed Consent 388 
Form. The contact information for the study will be  maintained in a secure database and will be 389 
maintained separately from study data. 390 
Contact information is necessary for shipment of st udy supplies, set up of certain apps needed for 391 
the study on the participant’s personal smartphone,  and participant payments. Contact 392 
information will be used by virtual clinic team mem bers for training and follow up. Participants 393 
will receive reminders via text, email, or phone to  complete questionnaires or submit study data. 394 
Mobile number will be shared with parties involved in processing of data if the mobile number is 395 
required to send automated text reminders to minimi ze missing data. 396 
Communications will be provided to a health care pr ovider designated by the participant. 397 
5.6.1  Personal Healthcare Provider Information 398 
Participants will be asked to provide the contact i nformation of a health care provider that they 399 
designate for their diabetes management. Provider i nformation is necessary so that the provider 400 
can be made aware of the participant’s study partic ipation and of information related to care or 401 
treatment. Permission for communication to the desi gnated health care provider will be included 402 
in the Informed Consent Form. 403 
5.7  Confidentiality 404 
For security purposes, participants will be assigne d an identifier that will be used instead of their 405 
name. Protected health information gathered for thi s study will be shared with the JCHR 406 
coordinating center in Tampa, FL, virtual clinic an d study team members involved with 407 
participant training and review of CGM data, partic ipating institutions and investigators in the 408 
research study, and parties involved in collecting and processing of data in accordance with the 409 
terms of the study contracts. Participant calls wit h the virtual team members may be recorded. 410 
The informed consent form will specify entities tha t will have access to or receive data. 411 
No identifiable health information of an enrolled p articipant will be released by the coordinating 412 
center, except as described above. 413 
5.8  Quality Assurance and Monitoring 414 
Designated personnel from the coordinating center w ill be responsible for maintaining quality 415 
assurance and quality control systems to ensure tha t the trial is conducted, and that data are 416 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 23  OF 28 generated, documented and reported in compliance wi th the protocol, GCP and the applicable 417 
regulatory requirements. 418 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 24  OF 28 
 Statistical Considerations 419 
6.1  Statistical and Analysis Plan 420 
The approach to sample size and statistical analyse s are summarized below. A Statistical 421 
Analysis Plan (SAP) will be written and finalized p rior to the completion of the study. The 422 
analysis plan synopsis in this chapter contains the  framework of the anticipated final SAP. The 423 
SAP will describe the analyses to be performed for the primary manuscript. 424 
6.2  Sample Size 425 
The goal for the study is to include at least 300 p articipants who initiate training for CGM. This 426 
is a convenience sample and not based on statistica l principles. 427 
6.3  Outcome Measures 428 
The following outcome measures will be stratified b y type of diabetes.  429 
Efficacy Outcomes: 430 
 HbA1c 431 
 CGM use 432 
 Mean of sensor glucose levels 433 
 Percentage of time spent with sensor glucose levels  <54 and <70 mg/dL 434 
 Percentage of time spent with sensor glucose levels  >180 and >250 mg/dL 435 
 Percentage of time spent with sensor glucose levels  in the target range (70-180 mg/dL) 436 
 Glycemic variability measured by the coefficient of  variation 437 
 Insulin metrics 438 
 Questionnaire scores (and their corresponding subsc ales) 439 
 Psychosocial metrics 440 
 Healthcare utilization metrics 441 
 442 
CGM, HbA1c, and questionnaires outcomes will be eva luated at all time points they are 443 
collected.  444 
 445 
Safety Outcomes : Severe Hypoglycemia and DKA events, and hospitali zations 446 
6.4  Description of Statistical Methods 447 
6.4.1  Analysis Cohorts 448 
All subjects enrolled in the study who initiate the  CGM and have a minimum amount of data as 449 
defined in the SAP will be included in the tabulati ons of   baseline and the efficacy analyses. All 450 
subjects enrolled in this study will be included in  the safety analyses. 451 
6.5  Analysis of Efficacy Outcomes 452 
CGM metrics and HbA1c will be calculated and summar ized at 13, 26, 39, and 52 weeks. 453 
Summary statistics for questionnaires will be provi ded at all time points when they are collected. 454 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 25  OF 28 A linear mixed model with a random subject effect w ill be used to assess whether the change 455 
from baseline significantly differs from zero. If v alues are highly skewed, then the winsorized 456 
mean will be tested or a transformation utilized. A  complete-case analysis using a paired t-test or 457 
Wilcoxon signed rank test will also be assessed. 458 
6.6  Subgroup Analyses 459 
Subgroup analyses for HbA1c and selected CGM outcom es will be performed by baseline 460 
HbA1c group, insulin delivery modality, age, health care provider (endocrinologist or primary 461 
care provider), and various participant characteris tics as described in the SAP. 462 
6.7  Safety Analyses 463 
All adverse events that occur post enrollment will be listed in a table. Additionally, each of the 464 
following safety metrics will be tabulated for repo rted SH and DKA events, hospitalizations and 465 
emergency room visits: 466 
 Number of subjects with ≥1 event 467 
 Number of events per subject 468 
 Incidence rate per 100 person-years 469 
6.8  Baseline Descriptive Statistics 470 
Baseline demographic and clinical characteristics o f the cohort of all subjects who initiate the 471 
CGM will be summarized in a table.  472 
6.9  Multiple Comparisons/Multiplicity 473 
No adjustments for multiple comparisons will be mad e. 474 
6.10  Additional Analyses 475 
Several additional analyses will be performed in th is study. These will include the following: 476 
 Tabulations of CGM glycemia and CGM use by month an d comparing the first 26 weeks 477 
and last 26 weeks of the study (overall and within subgroups) 478 
 Tabulations of CGM glycemia by time of day 479 
 Tabulations of the number of participant contacts w ith the virtual clinic 480 
 Bivariate relationship between questionnaires and g lycemic metrics following CGM 481 
initiation 482 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 26  OF 28 
 Ethics/Protection of Human Participants 483 
7.1  Ethical Standard 484 
The investigator will ensure that this study is con ducted in full conformity with Regulations for 485 
the Protection of Human Participants of Research co dified in 45 CFR Part 46, 21 CFR Part 50, 486 
21 CFR Part 56, and/or the ICH E6. 487 
7.2  Institutional Review Boards 488 
The protocol, informed consent form(s), recruitment  materials, and all participant materials will 489 
be submitted to the IRB for review and approval. Ap proval of both the protocol and the consent 490 
form must be obtained before any participant is enr olled. Any amendment to the protocol will 491 
require review and approval by the IRB before the c hanges are implemented to the study. All 492 
changes to the consent form will be IRB approved; a  determination will be made regarding 493 
whether previously consented participants need to b e re-consented. 494 
7.3  Informed Consent Process 495 
7.3.1  Consent Procedures and Documentation 496 
Informed consent is a process that is initiated pri or to the individual’s agreeing to participate in 497 
the study and continues throughout the individual’s  study participation. Individuals who indicate 498 
that they are interested in study participation wil l be directed to a website with information about 499 
the study. Interested individuals will be able to h ave a live chat or arrange for a phone call to 500 
answer questions about the study as part of the inf ormed consent process. Participants who want 501 
to participate in the study will sign the IRB-appro ved electronic consent form. 502 
The participants should have the opportunity to dis cuss the study with their surrogates or think 503 
about it prior to agreeing to participate. The part icipant will sign the informed consent document 504 
prior to any procedures being done specifically for  the study. The participant may withdraw 505 
consent at any time throughout the course of the st udy. The participant will be able to print a 506 
copy of the informed consent document for their rec ords. The rights and welfare of the 507 
participants will be protected by emphasizing to th em that the quality of their medical care will 508 
not be adversely affected if they decline to partic ipate in this study. 509 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 27  OF 28 
 References 510 
1. Acciaroli G, Vettoretti M, Facchinetti A, Sparac ino G. Toward calibration-free 511 
continuous glucose monitoring sensors: Bayesian cal ibration approach applied to next- 512 
generation Dexcom technology. Diabetes Technology & Therapeutics. 2018;20(1):59-67. 513 
2. Bailey TS, Chang A, Christiansen M. Clinical acc uracy of a continuous glucose 514 
monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015;9(2):209- 515 
214. 516 
3. Beck R, Riddlesworth T, Ruedy K, et al. Effect o f continuous glucose monitoring on 517 
glycemic control in adults with Type 1 Diabetes usi ng insulin injections: The DIAMOND 518 
randomized clinical trial. JAMA. 2017;317(4):371-378. 519 
4. Bergenstal RM, Tamborlane WV, Ahmann A, et al. E ffectiveness of sensor-augmented 520 
insulin-pump therapy in Type 1 Diabetes. New England Journal of Medicine. 521 
2010;363(4):311-320. 522 
5. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr öger J, Weitgasser R. Novel glucose- 523 
sensing technology and hypoglycaemia in Type 1 Diab etes: A multicentre, non-masked, 524 
randomised controlled trial. Lancet. 2016;388(10057):2254-2263. 525 
6. Heinemann L, Freckmann G, Ehrmann D, et al. Real -time continuous glucose monitoring 526 
in adults with Type 1 Diabetes and impaired hypogly caemia awareness or severe 527 
hypoglycaemia treated with multiple daily insulin i njections (HypoDE): A multicentre, 528 
randomised controlled trial. Lancet. 2018;391(10128):1367-1377. 529 
7. Juvenile Diabetes Research Foundation Continuous  Glucose Monitoring Study Group, 530 
Beck R, Hirsch I, et al. The effect of continuous g lucose monitoring in well-controlled 531 
Type 1 Diabetes. Diabetes Care. 2009;32:1378-1383. 532 
8. Juvenile Diabetes Research Foundation Continuous  Glucose Monitoring Study Group, 533 
Tamborlane W, Beck R, et al. Continuous glucose mon itoring and intensive treatment of 534 
Type 1 Diabetes. New England Journal of Medicine. 2008;359(14):1464-1476. 535 
9. Lind M, Polonsky W, Hirsch I, et al. Continuous glucose monitoring vs conventional 536 
therapy for glycemic control in adults with Type 1 Diabetes treated with multiple daily 537 
insulin injections: The GOLD randomized clinical tr ial JAMA. 2017;317(4):379-387. 538 
10. Little S, Leelarathna L, Walkinshaw E, et al. R ecovery of hypoglycemia awareness in 539 
long-standing Type 1 Diabetes: A multicenter, 2 x 2  factorial, randomized controlled trial 540 
comparing insulin pump with multiple daily injectio ns and continuous with conventional 541 
glucose self-monitoring (HypoCOMPaSS). Diabetes Care. 2014;37:2114-2122. 542 
11. Cox DJ, Taylor A, Moncrief M, et al. Continuous  glucose monitoring in the self- 543 
management of Type 2 Diabetes: A paradigm shift. Diabetes Care. 2016;39(5):e71-e73. 544 
12. Vigersky R, Shrivastav M. Role of continuous gl ucose monitoring for Type 2 in diabetes 545 
management and research. Journal of Diabetes and its Complications. 2017;31(1):280- 546 
287. 547 
13. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term 548 
effects of real-time continuous glucose monitoring in patients with Type 2 Diabetes. 549 
Diabetes Care. 2012;35(1):32-38. 550 
14. Foster N, RW. B, Miller K, et al. State of Type  1 Diabetes management and outcomes 551 
from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics. 552 
2019;21(2):66-72. 553 
JAEB CENTER FOR HEALTH RESEARCH  
VDISC  PROTOCOL  7-6-21_ V 4.1DD 34-7292- D1E1-DB 79 
 P AGE 28  OF 28 15. Beck RW, Riddlesworth TD, Ruedy K, et al. Conti nuous glucose monitoring versus usual 554 
care in patients with Type 2 Diabetes receiving mul tiple daily insulin injections: A 555 
randomized trial. Annals of Internal Medicine. 2017;167(6):365-374. 556 
16. Haak T, Hanaire H, Ajjan R, Hermanns N, Rivelin e J, Rayman G. Flash glucose-sensing 557 
technology as a replacement for blood glucose monit oring for the management of insulin- 558 
treated Type 2 diabetes: A multicenter, open-label randomized controlled trial. Diabetes 559 
Therapy. 2016;8(1):55-73. 560 
17. Polonsky WH, Hessler D. What are the quality of  life-related benefits and losses 561 
associated with real-time continuous glucose monito ring? A survey of current users. 562 
Diabetes Technol Ther. 2013;15(4):295-301. 563 
18. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, Grou p DS. The Impact of Continuous 564 
Glucose Monitoring on Markers of Quality of Life in  Adults With Type 1 Diabetes: 565 
Further Findings From the DIAMOND Randomized Clinic al Trial. Diabetes Care. 566 
2017;40(6):736-741. 567 
19. Healy AM, Shubrook JH, Schwartz FL, Cummings DM , Drake AJ, Tanenberg RJ. 568 
Endocrinologists’ opinions of diabetology as a prim ary care subspecialty. Clinical 569 
Diabetes. 2018;36(2):168-173. 570 
20. Pettus J, Zhou F, Shepherd L, et al. Incidences  of severe hypoglycemia and diabetic 571 
ketoacidosis and prevalence of microvascular compli cations stratified by age and 572 
glycemic control in U.S. adult patients With Type 1  Diabetes: A real-world study. 573 
Diabetes Care. 2019:dc190830. 574 
21. Vigersky R, Fish L, Hogan P, et al. The clinica l endocrinology workforce: Current status 575 
and future projections of supply and demand. The Journal of Clinical Endocrinology & 576 
Metabolism. 2014;99(9):3112-3121. 577 
22. Naranjo D, Tanenbaum ML, Iturralde E, Hood KK. Diabetes technology: Uptake, 578 
outcomes, barriers, and the intersection with distr ess. J Diabetes Sci Technol. 579 
2016;10(4):852-858. 580 
23. Battelino T, Danne T, Bergenstal R, et al. Clin ical targets for continuous glucose 581 
monitoring data interpretation: Recommendations fro m the international consensus on 582 
time in range. Diabetes Care. 2019;42(8):1593-1603. 583 